Aptar Pharma announced today that it entered into a contract with the FDA to work on low global warming potential (low-GWP) inhalers.
The FDA enlisted Aptar intends to study the challenges of developing low-GWP propellant metered dose inhalers (MDIs). The Crystal Lake, Illinois-based company expects its study to help define the potential target product profile of low-GWP propellant MDIs. It hopes to achieve comparability in critical quality attributes to existing MDIs.
Aptar values the contracted work, which includes “optional contract line items,” at approximately $6 million.
Get the full story at our sister site, Drug Delivery Business News.